217
Participants
Start Date
December 4, 2006
Primary Completion Date
January 4, 2008
Study Completion Date
January 4, 2008
SPD503 (Guanfacine hydrochloride)
Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
Placebo
Placebo
Mount Sinai School of Medicine, New York
SUNY Upsate Medical University, Syracuse
University of Rochester, School of Medicine and Dentistry, Rochester
University of Pittsburgh Medical Center, Pittsburgh
CRI Worldwide, LLC, Philadelphia
NeuroScience, Inc, Herndon
Dominion Clinical Research, Midlothian
Duke Child & Family Study Center, Durham
Piedmont Neuropsychiatry, Charlotte
Sarkis Clinical Trials, Gainesville
University of Florida, Gainesville
CORE Research, Inc, Maitland
Childrens Developmental Center, Winter Park
Clinical Neuroscience Solutions, Inc, Orlando
Amedica Research Institute, Inc, Hialeah
Miami Research Associates, Miami
Four Rivers Clinical Research, Paducah
Pedia Research, Owensboro
Discovery and Wellness Center for Children, Cleveland
University of Cincinnati, Cincinnati
Capstone Clinical Research, Libertyville
Vince and Associates Clinical Research, Overland Park
University of Nebraska Medical Center, Omaha
IPS Research Company, Oklahoma City
BHI Inc, Moore
Claghorn-Lesem Research Clinic Inc, Houston
Red Oak Psychiatry Associates, PA, Houston
HOPE Research Institute, Phoenix
Peninsula Research Associates Inc, Rolling Hills Estates
Valley Clinical Research, El Centro
Oregon Center for Clinical Investigations, Inc, Portland
Oregon Center for Clinical Investigations, Inc, Salem
Eastside Therapeutic Resource, Kirkland
CRI Worldwide, LLC, Clementon
Lead Sponsor
Shire
INDUSTRY